Literature DB >> 18503352

Radiosurgery for glomus jugulare tumors: experience treating 16 patients in Iran.

Mohammad Ali Bitaraf1, Mazdak Alikhani, Pouya Tahsili-Fahadan, Rouzbeh Motiei-Langroudi, Alireza Zahiri, Mahmoud Allahverdi, Soraya Salmanian.   

Abstract

OBJECT: Glomus jugulare tumors (GJT) have traditionally been treated by surgery or fractionated external-beam radiotherapy. The aim of this retrospective study was to determine the tumor control rate, clinical outcome, and short-term complications of stereotactic radiosurgery in subsets of patients who are poor candidates for these procedures, based on age, medical problems, tumor size, or prior treatment failure.
METHODS: The Leksell Gamma Knife was used to treat 16 patients harboring symptomatic, residual, recurrent, or unresectable GJTs. The age of the patients ranged from 12 to 77 years (median 46.5 years). Gamma Knife surgery (GKS) was performed as primary treatment in five patients (31.3%). Microsurgery preceded radiosurgery in 10 patients (62.5%) and fractionated radiotherapy in three patients (18.8%). The median tumor volume was 9.8 cm3 (range 1.7-20.6 cm3). The median marginal dose applied to a mean isodose volume of 50% (range 37-70%) was 18 Gy (range 14-20 Gy). Neurological follow-up examinations revealed improved clinical status in 10 patients (62.5%), a stable neurological status in six (37.5%), and no complications. After radiosurgery, follow-up imaging was conducted in 14 patients; the median interval from GKS to the last follow up was 18.5 months (range 4-28 months). Tumor size had decreased in six patients (42.9%), and the volume remained unchanged in the remaining eight (57.1%). None of the tumors increased in volume during the observation period.
CONCLUSIONS: According to the authors' experience, GKS represents a useful therapeutic option to control symptoms and may be safely conducted in patients with primary or recurrent GJTs with no death and no acute morbidity. Because of the tumor's naturally slow growth rate, however, long-term follow-up data are needed to establish a cure rate after radiosurgery.

Entities:  

Mesh:

Year:  2006        PMID: 18503352     DOI: 10.3171/sup.2006.105.7.168

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Stereotactic radiosurgery of glomus jugulare tumors: current concepts, recent advances and future perspectives.

Authors:  Omer Sager; Ferrat Dincoglan; Murat Beyzadeoglu
Journal:  CNS Oncol       Date:  2015

Review 2.  Radiosurgery of glomus jugulare tumors: a meta-analysis.

Authors:  Zachary D Guss; Sachin Batra; Charles J Limb; Gordon Li; Michael E Sughrue; Kristin Redmond; Daniele Rigamonti; Andrew T Parsa; Steven Chang; Lawrence Kleinberg; Michael Lim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-22       Impact factor: 7.038

3.  Toxicity of Gamma Knife Radiosurgery May Be Greater in Patients with Lower Cranial Nerve Schwannomas.

Authors:  Rawee Ruangkanchanasetr; John Y K Lee; Suneel N Nagda; Geoffrey A Geiger; James D Kolker; Douglas C Bigelow; Michael J Ruckenstein; MacLean Nasrallah; Michelle Alonso-Basanta
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-10

4.  Glomus tumors treated with stereotactic radiosurgery: A retrospective study.

Authors:  Victor Tse; Jussi Sillanpaa; Ann Y Minn; Ming Teng; Fu Xiaoyang; Amy Gillis; Laura Millender; William Sheridan; William Wara
Journal:  J Radiosurg SBRT       Date:  2017

5.  A 10-year experience of linear accelerator-based stereotactic radiosurgery/radiotherapy (SRS/SRT) for paraganglioma: A single institution experience and review of the literature.

Authors:  Michael J Gigliotti; Shaakir Hasan; Yun Liang; Douglas Chen; Russell Fuhrer; Rodney E Wegner
Journal:  J Radiosurg SBRT       Date:  2018

6.  Microsurgical treatment of large and giant tympanojugular paragangliomas.

Authors:  Ali Harati; Thomas Deitmer; Stefan Rohde; Alexander Ranft; Werner Weber; Rolf Schultheiß
Journal:  Surg Neurol Int       Date:  2014-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.